Psyence Biomedical Ltd. (PBM)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
Psyence Biomedical Ltd. has not issued a press release in this window.
SEC filings
All filings →Psyence Biomedical Ltd. has not filed an SEC document in this window.
Insider trades
All insider trades →Psyence Biomedical Ltd. has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for Psyence Biomedical Ltd. in this window.
People at Psyence Biomedical Ltd.
All people →No officers or directors have been indexed for Psyence Biomedical Ltd..
Quarterly financials
Full financials →No quarterly financials have been ingested for Psyence Biomedical Ltd..